Skip Navigation




Angiotensin II Receptor Antagonists


The angiotensin II receptor antagonists, also known as angiotensin receptor blockers (ARBs), are a family of agents that bind to and inhibit the angiotensin II type 1 receptor (AT1) and thus inhibit the renin-angiotensin system and its cascade of effects in causing arteriolar contraction and sodium retention.  While angiotensin converting enzyme (ACE) inhibitors block the cleavage of angiotensin I to angiotensin II, the active peptide that causes a pressor response, the ARBs inhibit its peripheral action.  The ARBs reduce blood pressure in animal models as well as in humans.  Since their introduction in 1995, these agents have been used widely in the therapy of hypertension and to reduce the complications of hypertensive cardiovascular disease and diabetic nephropathy.

The ARBs in clinical use in the United States include eight agents of similar chemical structure and activity, but somewhat different pharmacokinetics:  losartan (Cozaar: 1995), valsartan (Diovan: 1996), irbesartan (Avapro: 1997), eprosartan (Teveten: 1997), candesartan (Atacand: 1998), telmisartan (Micardis: 1998), olmesartan (Benicar: 2002) and azilsartan (Edarbi: 2011).  All of these agents have been associated with a minimal rate of serum enzyme elevations during chronic therapy (0.2% to 2%) which are usually mild-to-moderate in severity, self limited, and rarely require dose modification or discontinuation.  As a class, the ARBs have been associated with rare instances of acute liver injury that is usually self limited in duration, but varies in clinical expression, being usually hepatocellular but occasional cholestatic in nature.  The most common presentation of liver injury due to these agents is a cholestatic hepatitis arising within 1 to 8 weeks of starting and resolving as rapidly with stopping.  Rare instances of prolonged jaundice have been described but not acute liver failure or autoimmune chronic hepatitis.  Several Individual case reports of clinically apparent liver injury have been published in the literature for losartan, valsartan, irbesartan olmesartan and candesartan, but not specifically for azilsartan, eprosartan, and telmisartan, probably because these three have been in use for a shorter period of time and in fewer subjects.


Most ARBs and particularly olmesartan have been linked to rare instances of severe sprue-like enteropathy.  The enteropathy typically presents with severe diarrhea and weight loss with variable degrees of fatigue, nausea and abdominal discomfort arising 6 months to many years after starting the ARB.  Small intestinal histological findings resemble those of celiac disease with flattening of the duodenal villuous pattern and villous atrophy.  However, anti-transglutaminase and endomysial antibodies (the serologic markers of celiac disease) are negative and there is little or no response to a gluten-free diet.  Withdrawal of the ARB, however, results in prompt improvement in the diarrhea and gradual resolution of duodenal villous flattening.  Some cases of this drug induced enteropathy have had accompanying serum aminotransferase elevations and fatty liver by imaging or liver biopsy, which, along with the diarrhea, resolve rapidly with stopping the medication.

The different angiotensin II receptor antagonists are discussed separately, but references on their hepatotoxicity are given together after this introductory section.


The following links are to individual drug records.


Top of page


Angiotensin II Receptor Antagonists
Azilsartan 147403-03-0 C25-H20-N4-O5 Azilsartan Chemical Structure
Candesartan 139481-59-7 C24-H20-N6-O3 Chemical Structure for Candesartan
Eprosartan 133040-01-4 C23-H24-N2-O4-S Chemical Structure for Eprosartan
Irbesartan 138402-11-6 C25-H28-N6-O Chemical Structure for Irbesartan
Losartan 124750-99-8 C22-H23-Cl-N6-O.K Chemical Structure for Losartan
Olmesartan 144689-24-7 C24-H26-N6-O3 Chemical Structure for Olmesartan
Telmisartan 144701-48-4 C33-H30-N4-O2 Chemical Structure for Telmisartan
Valsartan 144701-48-4 C24-H29-N5-O3 Chemical Structure for Valsartan

Top of page

Angiotensin II Receptor Antagonists

References updated: 13 January 2017

  1. Zimmerman HJ. Cardiovascular agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 623-5.  (Expert review of hepatotoxicity published in 1999; mentions a single case of hepatotoxicity from losartan with a positive rechallenge [Bosch 1997]).

  2. De Marzio DH, Navarro VJ. Antihypertensives.  Hepatotoxicity of cardiovascular and antidiabetic medications. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 522-6.  (Review of hepatotoxicity of antihypertensive agents, mentions that cases of hepatotoxicity of candesartan, irbesartan, losartan and valsartan have been published, but none were fatal and were variable in both latency to onset [1 week to 6 months] and clinical presentation [cholestatic and hepatocellular]).

  3. Michel T, Hoffman BB. Treatment of myocardial ischemia and hypertension. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 745-88.  (Textbook of pharmacology and therapeutics).

  4. Hillal-Dandan R. Nonpeptide angiotensin II receptor antagonists. Renin and angiotensin. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 736-9.  (Textbook of pharmacology and therapeutics).

  5. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793-5. PubMed Citation  (Summary of adverse events during losartan therapy in prelicensure clinical trials in more than 2000 patients; most symptoms were no more frequent than with placebo; ALT elevations occurred in 1.9% of patients on losartan, but rates were similar in comparator arms).

  6. Nygaard B, Strandgaard S. Marked hepatotoxicity associated with losartan treatment. Blood Press 1996; 5: 190-1. PubMed Citation  (Two women developed anicteric hepatitis on losartan: 55 year old developed back pain 3 weeks after starting losartan [bilirubin 1.3 mg/dL, ALT 650 U/L, Alk P 396 U/L], resolving within a month of stopping; 46 year old developed chest pain “a few months” after starting losartan [ALT 311 U/L, no bilirubin or Alk P given], resolving within 2 weeks of stopping).

  7. MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278-85. PubMed Citation  (In a controlled trial of losartan with or without hydrochlorothiazide [HCTZ] vs placebo in 703 patients with hypertension, there were no overall changes in serum aminotransferase levels or serious adverse events or dose modifications for any laboratory abnormality).

  8. Bosch X. Losartan-induced hepatotoxicity. JAMA 1997; 278: 1572. PubMed Citation  (46 year old man developed jaundice one month after starting losartan [bilirubin 9.6 mg/dL, ALT 2574 U/L, Alk P 738 U/L], resolving within 4 months of stopping; 3 week rechallenge led to jaundice [Case 1 for losartan]; reply from Merck mentioning 80 reports of liver abnormalities among an estimated 2 million patients treated).

  9. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Human Hypertens 1997; 11 [Suppl 2]: S69-73. PubMed Citation  (Analysis of two phase III trials [489 and 298 patients] of candesartan in hypertension for 6 to 12 months found low rate of side effects [headache and back pain most frequent] and “No clinically relevant changes in laboratory parameters [apart from two cases of increased hepatic enzymes]”).

  10. Andrade RJ, Lucena MI, Santalla F. Hepatic injury associated with losartan. Ann Pharmacother 1998; 32: 1371. PubMed Citation  (77 year old man developed fatigue 3 weeks after starting an excessive dose of losartan [150 mg daily] for hypertension [bilirubin 1.7 mg/dL, ALT 410 U/L, Alk P normal], resolving within 4 weeks of stopping).

  11. McClellan KJ, Goa KL. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998; 56: 847-69. PubMed Citation  (Review of pharmacology, clinical use and safety of candesartan: studies in 4147 patients given doses of 8 or 16 mg daily found low rate of adverse events, headache in 10%, cough in 1.6%, similar rates with placebo; ALT elevations occur in “occasional” patients, reported in 2 of 632 patients in one trial of candesartan given for 12 months).

  12. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998; 55: 713-8. PubMed Citation  (Review of pharmacology, clinical studies and safety of eprosartan; tolerability at doses of 400 to 1200 mg daily was similar to placebo: no mention of ALT elevations or hepatotoxicity).

  13. McClellan KJ, Markham A. Telmisartan. Drugs 1998; 56: 1039-44. PubMed Citation  (Review of pharmacology, clinical studies and safety of telmisartan; tolerability at doses of 20 to 160 mg daily was similar to placebo: no mention of ALT elevations or hepatotoxicity).

  14. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23-33. PubMed Citation  (Review of safety and tolerability of different ARBs in clinical trials: “None of the compounds induced a clear, specific, dose dependent adverse effect that could be attributed to the drug": common complaints being headache, dizziness, and fatigue; ALT elevations occurred rarely and were transient and resolved despite continuation of therapy, only one case of ALT requiring discontinuation has been reported, with losartan and from the sponsor).

  15. Sega R. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999; 8: 114-21. PubMed Citation  (Among 118 patients with hypertension treated with eprosartan or enalapril for 2 weeks, side effects were mild and similar in both groups; ALT results not given).

  16. Shusterman NH. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker. Am Heart J 1999; 138 (3 Pt 2): 238-45. PubMed Citation  (Review of clinical efficacy and safety of eprosartan; no mention of hepatotoxicity or ALT elevations).

  17. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45. PubMed Citation  (Review of history, pharmacology, mechanism of action, clinical efficacy and safety of the angiotensin II receptor antagonists; “Occasional minor increases in liver enzymes were usually transient”).

  18. Hariraj R, Stoner E, Jader S, Preston DM. Drug points: prolonged cholestasis associated with irbesartan. BMJ 2000; 321: 547. PubMed Citation  (62 year old developed jaundice 1 month after starting irbesartan with bilirubin 23.6 mg/dL, AST 177 U/L, Alk P 3193 U/L, slow recovery, 2 biopsies).

  19. González-Jiménez D, Varela JM, Calderón E, Galindo J, González de la Puente MA. Candesartan and acute liver injury. Eur J Clin Pharmacol 2000; 56: 769-70. PubMed Citation  (70 year old developed abdominal pain and jaundice 2 weeks after starting candesartan with bilirubin 21 mg/dL, ALT 244 U/L, Alk P 221 U/L, resolution in 2 months).

  20. Vallejo I, García Morillo S, Pamies E. [Acute hepatitis induced by candesartan]. Med Clin (Barc) 2000; 115: 719. Spanish. PubMed Citation  (41 year old developed jaundice 5 weeks after starting candesartan [bilirubin 20 mg/dL, ALT 2700 U/L, Alk P 321 U/L], resolved with stopping).

  21. Markham A, Spencer CM, Jarvis B. Irbesartan: an updated review of its use in cardiovascular disorders. Drugs. 2000; 59: 1187-206. PubMed Citation  (Review of pharmacology, clinical use and side effects of irbesartan; analysis of pooled data from 9 studies in 2606 patients found low rate of adverse events; no mention of hepatotoxicity or ALT elevations).

  22. Reñé JM, Buenestado J, Sesé E, Miñana JM. Acute hepatitis induced by valsartan. Med Clin (Barc) 2001; 117: 637-8. PubMed Citation  (54 year old woman developed jaundice 18 weeks after starting valsartan for hypertension [bilirubin 23.6 mg/dL, ALT 1664 U/L, Alk P 385 U/L], resolving within 2 months of stopping).

  23. Chitturi S, Farrell GC. Drug-induced cholestasis. Semin Gastrointest Dis 2001; 12: 113-24. PubMed Citation  (Review of the causes of drug induced liver injury with cholestatic features).

  24. Andrade RJ, Lucena MI, Fernández MC, Vega JL, García-Cortés M, Casado M, Guerrero-Sanchez E, et al. Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. Eur J Gastroenterol Hepatol 2002; 14: 887-90. PubMed Citation  (56 year old man developed jaundice 8 days after starting irbesartan [bilirubin 7.5 to 16.1 mg/dL, ALT 2646 U/L, Alk P 305 U/L], with Alk P remaining elevated for 16 months, but biopsy not showing vanishing bile ducts).

  25. Tabak F, Mert A, Ozaras R, Biyikli M, Ozturk R, Ozbay G, Senturk H, et al. Losartan-induced hepatic injury. J Clin Gastroenterol 2002; 34: 585-6. PubMed Citation  (52 year old woman developed jaundice 5 month after starting losartan [bilirubin not given, ALT 750 U/L], resolving after stopping but recurring within 2 weeks of restarting [bilirubin 8.9 mg/dL, ALT 941 U/L, Alk P 419 U/L], then resolving within 4 months of stopping).

  26. Basile G, Villari D, Gangemi S, Ferrara T, Accetta MG, Nicita-Mauro V. Candesartan cilexetil-induced severe hepatotoxicity. J Clin Gastroenterol 2003; 36: 273-5. PubMed Citation  (61 year old woman developed fever, abdominal pain and jaundice 1 month after starting candesartan [bilirubin 27.2 rising to 46.8 mg/dL, ALT 918 U/L, Alk P 142 U/L], resolving in 8 weeks with prednisone therapy, biopsy showing bile duct loss and fibrosis: Case 1 of candesartan).

  27. Kiykim A, Altintas E, Sezgin O, Sezer K, Tiftik N, Akbay E, Seyrek E, et al. Valsartan-induced hepatotoxicity in a HBsAg-Positive patient. Am J Gastroenterol 2003; 98: 507. PubMed Citation  (52 year old woman with hypertension and HBsAg without chronic ALT elevations developed jaundice 4 weeks after starting valsartan [peak bilirubin 7.8 mg/dL, ALT 780 U/L, Alk P 1840 U/L], resolving within 3 months of stopping).

  28. Foruny Olcina JR, Moreira Vicente VF, Gómez García M, Morell Hita JL. [Irbesartan-induced acute hepatitis] Gastroenterol Hepatol 2004; 27: 71-2. Spanish. PubMed Citation  (59 year old developed jaundice 2 weeks after starting irbesartan [bilirubin 8.5 mg/dL, ALT 1378 U/L, Alk P 244 U/L], slow resolution over 4 months).

  29. Péron JM, Robic MA, Bureau C, Vinel JP. [Irbesartan induced acute hepatitis:
    one case]. Gastroenterol Clin Biol 2005; 29: 747-8. French. PubMed Citation  (51 year old woman with fatty liver developed urticaria and myalgias 3 weeks after starting irbesartan [ALT 890 U/L, Alk P and bilirubin not given], resolving within 2-3 weeks of stopping).

  30. Annicchiarico BE, Siciliano M. Could irbesartan trigger autoimmune cholestatic hepatitis? Eur J Gastroenterol Hepatol 2005; 17: 247-8. PubMed Citation  (69 year old man developed jaundice 1 month after starting irbesartan [bilirubin 31.9 mg/dL, ALT 1449 U/L, Alk P 515 U/L, ANA negative and normal IgG], responsing to corticosteroids, but relapsing on stopping, but then resolving without relapse after 2 years of corticosteroid therapy, still autoantibody negative).

  31. White WB, Punzi HA, Murwin D, Koval SE, Davidai G, Neutel JM. Effects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertension. J Clin Hypertens(Greenwich) 2006; 8: 626-33. PubMed Citation  (Among 1109 patients with hypertension treated with either telmisartan or valsartan or placebo, therapy was well tolerated; no mention of ALT levels or liver injury).

  32. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 2004; 10: 1018-23. PubMed Citation  (Among ~50,000 liver transplants done in the United States between 1990 and 2002, 270 [0.5%] were done for drug induced acute liver failure, but no case was attributed to an angiotensin receptor blocker).

  33. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

    Gastroenterology 2008; 135: 1924-34. PubMed Citation  (Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, no cases were attributed to an angiotensin receptor blocker).

  34. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008; 1: 32-40. PubMed Citation  (Among all patients enrolled in 50 clinical trials of telmisartan [~8000] alone or in combination with HCTZ, "hepatobiliary system disorders" developed in 0.1% of patients and changes in liver enzymes in <0.1%, but no details or definitions given).

  35. Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens(Greenwich) 2009; 11: 475-82. PubMed Citation  (Among 1940 patients with hypertension treated for 8 weeks with varying combinations of olmesartan, amlodipine and placebo, safety and tolerability were comparable among groups: no mention of ALT elevations or liver injury).

  36. Destro M, Preti P, D'Ospina A, Christian Achiri NN, Ricci AR, Cagnoni F. Olmesartan medoxomil: recent clinical and experimental acquisitions. Expert Opin Drug Metab Toxicol 2009; 5: 1149-57. PubMed Citation  (Review of olmesartan, 7th ARB approved for use in the United States, given as a medoxomil prodrug which is esterified during absorption; not metabolized by P450 system and rates of side effects are similar to those with placebo and include headache, dizziness and flu-like symptoms; no mention of ALT elevations or liver toxicity).

  37. Punzi HA. Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Rev Cardiovasc Ther 2009; 7: 229-39. PubMed Citation  (Review of olmesartan, a specific inhibitor of the angiotensin II type 1 receptor [AT1] taken as a medoxomil prodrug, few drug-drug interactions, effective alone or in combinations, particularly with hydrochlorothiazide, well tolerated with only slightly increased frequency of side effects compared to placebo [dizziness]; no mention of ALT elevations or liver toxicity). 

  38. Drugs for hypertension. Treat Guidel Med Lett 2009; 7: 1-10. PubMed Citation  (Brief overview of drugs for hypertension with guidelines on their use with information on prices and toxicities, mentions that side effects of angiotensin II receptor antagonists are similar to those of ACE inhibitors but they do not cause cough and only rarely cause angioedema, loss of taste and hepatoxicity).

  39. Jiménez-Sáenz M, Arroyo Q, Sanjuan M, Herrerías JM. [Candesartan-induced cholestatic hepatitis: a case report]. Gastroenterol Hepatol 2010; 33: 66-7. Spanish. PubMed Citation  (82 year old man developed jaundice 3 weeks after starting candesartan [bilirubin 6.8 rising to 22.2 mg/dL, ALT 272 U/L, Alk P 1045 U/L], resolving 8 weeks after stopping with prednisone therapy).

  40. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76. PubMed Citation  (Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, two of which were atttributed to antihypertensive agents [hydralazine and methyldopa], but none to angiotensive II receptor blockers).

  41. Oertelt-Prigione S, Crosignani A, Gallieni M, Vassallo E, Podda M, Zuin M. Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report. J Med Case Reports 2010; 4: 141. PubMed Citation  (40 year old man with cirrhosis and nephrotic syndrome developed coma within a day of adding ramipril to losartan, therapy with marked elevation in ammonia levels, recovery within days of stopping and recurrence on restarting the combination).

  42. Taglietti F, Del Nonno F, Baiocchini A, Falasca L, Pieri S, Capone A, Grilli E, et al. Acute hepatocellular and cholestatic injury during therapy with hydrochlorothiazide - clinicohistopathologic findings: a case report. J Med Case Rep 2010; 4: 332. PubMed Citation  (68 year old man developed fatigue and jaundice 10 days after starting hydrochlorothiazide and olmesartan [bilirubin 6.3 rising to 14.7 mg/dL, ALT 346 U/L, Alk P 1091 U/L], resolving within 3 months of stopping both drugs).

  43. Baker WL, White WB. Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother 2011; 45: 1506-15. PubMed Citation  (Systematic review of literature on safety and efficacy of azilsartan identified 3 full publications and 5 abstracts describing clinical trials; "Other laboratory findings, such as increases in serum creatinine or liver enzyme levels, occurred infrequently and at similar rates between all groups"; no mention of hepatotoxicity or clinically apparent liver injury).

  44. Azilsartan medoxomil (Edarbi) the eighth ARB. Med Lett Drugs Ther 2011; 53(1364): 39-40. PubMed Citation  (Concise summary of the clinical efficacy, safety and costs of azilsartan shortly after its approval in the US; hepatotoxicity was not mentioned). 

  45. Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012: 87: 732-8. PubMed Citation  (Clinical description of 22 patients with suspected olmesartan induced enteropathy, ages 47 to 81 years, presenting with chronic diarrhea, weight loss and fatigue arising 0.5-7 years after starting olmesartan, with villous flattening and atrophy on intestinal biopsy, lack of anti-endomyoseal and transglutaminase antibodies, not respondive to a gluten-free diet, but resolving promptly on stopping olmesartan and subsequent improvement in intestinal histology and ability to tolerate reintroduction of gluten).

  46. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25. PubMed Citation  (In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to antihypertensive agents or to angiotensin II receptor blockers).

  47. Cyrany J, Vasatko T, Machac J, Nova M, Szanyi J, Kopacova M. Letter: telmisartan-associated enteropathy - is there any class effect? Aliment Pharmacol Ther 2014; 40: 569-70. PubMed Citation(71 year old woman developed diarrhea, weight loss, and duodenal villous atrophy, arising 2 months after starting telmisasrtan and resolving with stopping and without gluten withdrawal; no mention of liver test results).

  48. Ianiro G, Bibbò S, Montalto M, Ricci R, Gasbarrini A, Cammarota G. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther 2014; 40: 16-23. PubMed Citation  (Systematic review of 11 publications on olmesartan associated enteropathy in 54 patients, ages 47 to 87 years, half women, arising 6 months to 7 years after starting drug, marked by villous flattening and atrophy, absence of typical celiac-associated autoantibodies, non-response to gluten free diet, but prompt resolution with stopping olmesartan).

  49. Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9. PubMed Citation  (Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, none of which were attributed to an angiotensin II receptor blocker).

  50. Al-Halawani MZ, Thawabi M, Asslo F, Shaaban H, Shamoon F, Baddoura WJ. Losartan-induced ischemic hepatocellular hepatotoxicity: a case report and literature review. J Family Med Prim Care 2014; 3: 272-4. PubMed Citation  (65 year old woman developed abdominal pain and anusea 4 months after starting losartan for hypertension [bilirubin 2.7 mg/dL, ALT 1184 U/L, Alk P 142 U/L], with rapid improvement within 1-2 weeks of stopping).

  51. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.  PubMed Citation  (Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 39 were attributed to antihypertensive medications including one each to losartan, irbesartan and valsartan).

  52. Negro A, Rossi GM, Santi R, Iori V, De Marco L. A case of severe sprue-like enteropathy associated with losartan. J Clin Gastroenterol 2015; 49: 794. PubMed Citation  (A 69 year old man developed chronic diarrhea, weight loss, anemia and low albumin, 3 years after starting losartan for hypertension with prompt resolution on stopping; no mention of liver test results).

  53. Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J 2015; 2: 92-4. PubMed Citation  (71 year old woman with long history of refractory sprue unresponsive to gluten withdrawal had a prompt remission when valsartan was discontinued [duration of therapy not provided]; no mention of liver test abnormalities).

  54. Non-Alcoholic Fatty Liver Disease Study Group, Dolci M, Nascimbeni F, Romagnoli D, Reggiani Bonetti L, Guaraldi G, Mascia MT, Lonardo A. Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy. Dig Liver Dis 2016; 48: 1399-1401. PubMed Citation  (72 year old man developed fatigue and diarrhea 3 years after starting olmesartan [ALT 202, Alk P and bilirubin not given, liver biopsy showing steatosis, duodenal biopsy partial villous atrophy], with prompt resolution of ALT elevations and diarrhea within 3 weeks of stopping olmesartan).

Top of page


Angiotensin II Receptor Antagonists
  1. PubMed logoRecent References on Angiotensin II Receptor Antagonists

  2. Clinical Trials logoTrials on Angiotensin II Receptor Antagonists

Top of page